Mass Spectrometry and Surface Plasmon Resonance (SPR) Innovations in Pharma
March 18 - March 19
Building on years of excellence in Mass Spectrometry, Bruker has developed a new set of technologies that are impacting the pharmacological related industry far beyond the traditional role of quantitation and process monitoring. From lead generation all the way through to pre-clinical assessment, drug companies are employing this advanced MS and SPR based technologies in a wide range of roles to increase the speed and specificity of hit finding, ADME/tox, PK/PD and KDon/KDoff studies, drug-to-target validation studies, and much more. Come join several industry leaders from top pharma around the globe as they present their perspectives on using these advances to streamline the drug development process.